✦ LIBER ✦

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

✍ Scribed by Francesco D’Amore; John Radford; Thomas Relander; Mats Jerkeman; Hervé Tilly; Anders Österborg; Franck Morschhauser; Martin Gramatzki; Martin Dreyling; Bo Bang; Hans Hagberg

Book ID: 108676887
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 279 KB
Volume: 150
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2010.08298.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of denileukin diftitox fo

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

✍ Nam H. Dang; Barbara Pro; Fredrick B. Hagemeister; Felipe Samaniego; Dan Jones; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 507 KB

Phase II Study of Cladribine (2-Chlorode

Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma

✍ Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 82 KB

Laboratory correlates for a phase II tri

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

✍ Susan E. Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB

Phase II study of the irinotecan (CPT-11

Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma

✍ Nozomi Niitsu; Mika Kohori; Masaaki Higashihara; Masami Bessho 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Phase II trial of the combination of den

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

✍ Nam H. Dang; Luis Fayad; Peter McLaughlin; Jorge E. Romaguara; Fredrick Hagemeis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB

Thalidomide has limited single-agent act

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B

✍ Sonali M. Smith; David Grinblatt; Jeffrey L. Johnson; Donna Niedzwiecki; David R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB